- Home
- ANIX vs CNTX Comparison
ANIX vs CNTX Comparison
Compare ANIX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- CNTX
- Stock Information
- Founded
- ANIX 1982
- CNTX 2015
- Country
- ANIX United States
- CNTX United States
- Employees
- ANIX N/A
- CNTX N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- CNTX Health Care
- Exchange
- ANIX Nasdaq
- CNTX Nasdaq
- Market Cap
- ANIX 95.7M
- CNTX 78.0M
- IPO Year
- ANIX 1987
- CNTX 2021
- Fundamental
- Price
- ANIX $3.06
- CNTX $0.89
- Analyst Decision
- ANIX Strong Buy
- CNTX Strong Buy
- Analyst Count
- ANIX 3
- CNTX 5
- Target Price
- ANIX $9.00
- CNTX $5.25
- AVG Volume (30 Days)
- ANIX 81.9K
- CNTX 183.1K
- Earning Date
- ANIX 09-05-2025
- CNTX 08-06-2025
- Dividend Yield
- ANIX N/A
- CNTX N/A
- EPS Growth
- ANIX N/A
- CNTX N/A
- EPS
- ANIX N/A
- CNTX N/A
- Revenue
- ANIX N/A
- CNTX N/A
- Revenue This Year
- ANIX N/A
- CNTX N/A
- Revenue Next Year
- ANIX N/A
- CNTX N/A
- P/E Ratio
- ANIX N/A
- CNTX N/A
- Revenue Growth
- ANIX N/A
- CNTX N/A
- 52 Week Low
- ANIX $2.07
- CNTX $0.49
- 52 Week High
- ANIX $4.20
- CNTX $2.62
- Technical
- Relative Strength Index (RSI)
- ANIX 49.07
- CNTX 66.26
- Support Level
- ANIX $2.92
- CNTX $0.85
- Resistance Level
- ANIX $3.07
- CNTX $0.94
- Average True Range (ATR)
- ANIX 0.12
- CNTX 0.05
- MACD
- ANIX -0.00
- CNTX 0.02
- Stochastic Oscillator
- ANIX 41.03
- CNTX 82.20
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.